BioCentury | Apr 7, 2021
Deals

Radioligand target deal with Novartis expands Artios’ runway and remit

...for $3.9 billion in 2017 and $2.1 billion in 2018, respectively.The former deal gave Novartis Lutathera...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...gaining the lutetium 177-based neuroendocrine tumor drug Lutathera...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...SIX:ROG; OTCQX:RHHBY) in 2014.The commercial success of Lutathera...
...in a space once left for dead. Novartis gained Lutathera...
...shorter path length compared with β-emitters, such as Lutathera’s...
BioCentury | Jan 29, 2020
Company News

Launches fuel Novartis’ growth as CEO reiterates China commitment

...then submit a BLA as early as mid-year. Novartis reiterated its blockbuster expectations for radiotherapy Lutathera...
...Schaffert said. Lutathera is approved to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Novartis gained Lutathera...
...Narasimhan” ). Erin McCallister, Senior Editor Zolgensma, onasemnogene abeparvovec-xioi, ScAAV9.CB.SMN (AVXS-101, charisma) Lutathera (Brand), 177-Lu-Dotatate (Informal), 177Lu-DOTA0-Tyr3-Octreotate (Informal), Lutetium Lu 177 Dotatate...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...Applications S.A. (AAA) for $3.9 billion in 2017, gaining the lutetium 177-based neuroendocrine tumor drug Lutathera...
...German biotech ABX GmbH in 2017 for $177.6 million in total deal value. Novartis highlighted Lutathera...
...and beta-emitting radiotherapies. Source: Company websites Karen Tkach Tuzman, Associate Editor Lutathera (Brand), 177-Lu-Dotatate (Informal), 177Lu-DOTA0-Tyr3-Octreotate (Informal), Lutetium Lu 177 Dotatate...
BioCentury | Oct 3, 2019
Politics & Policy

Experimental GBM vaccine available under U.S. right-to-try program

...rare, the Goldwater Institute also says it has persuaded a doctor in Texas to offer 177-Lu-Dotatate...
BioCentury | Jul 19, 2019
Company News

Payers, patients coming on board for Novartis’ Zolgensma

...81% from 2Q18. The oncology portfolio increased 9% driven by sales of neuroendocrine tumor therapy Lutathera...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...serves as the hub for the pharma’s radiotherapy product candidates. The acquisition gave Novartis Lutathera (177-Lu-Dotatate...
...Vascular endothelial growth factor Erin McCallister, Senior Editor brolucizumab (RTH258, esba1008) Lutathera (Brand), 177-Lu-Dotatate (Informal), 177Lu-DOTA0-Tyr3-Octreotate (Informal), Lutetium Lu 177 Dotatate...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...pibrentasvir (Mavyret - U.S.) HCV EU, Japan, Switzerland, U.S. $2,619.0 Novartis AG (NYSE:NVS; SIX:NOVN) Lutathera 177-Lu-Dotatate...
...Kymriah tisagenlecleucel ALL and DLBCL Australia, EU U.S. in 2017 Novartis AG (NYSE:NVS; SIX:NOVN) Lutathera lutetium Lu 177 dotatate...
BioCentury | Oct 19, 2018
Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

...Grants Endocyte Exclusive, Worldwide Rights to PSMA-Targeting Ligand" ). In January, FDA approved Novartis' Lutathera (177-Lu-Dotatate...
...first radiopharmaceutical the agency has approved to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The pharma gained Lutathera...
Items per page:
1 - 10 of 57